Search Results - "Rule, Simon A."

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies by Walter, Harriet S., Rule, Simon A., Dyer, Martin J.S., Karlin, Lionel, Jones, Ceri, Cazin, Bruno, Quittet, Philippe, Shah, Nimish, Hutchinson, Claire V., Honda, Hideyuki, Duffy, Kevin, Birkett, Joseph, Jamieson, Virginia, Courtenay-Luck, Nigel, Yoshizawa, Toshio, Sharpe, John, Ohno, Tomoya, Abe, Shinichiro, Nishimura, Akihisa, Cartron, Guillaume, Morschhauser, Franck, Fegan, Christopher, Salles, Gilles

“…We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with…”
Get full text

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences by Eve, Heather E., Carey, Sean, Richardson, Sarah J., Heise, Carla C., Mamidipudi, Vidya, Shi, Tao, Radford, John A., Auer, Rebecca L., Bullard, Sheila H., Rule, Simon A. J.

“…Summary We present data from a phase II study investigating a novel treatment strategy for relapsed/refractory mantle cell lymphoma (MCL). Twenty‐six patients…”
Get full text

Lenalidomide‐induced tumour flare reaction in mantle cell lymphoma by Eve, Heather E., Rule, Simon A. J.

Get full text

Autoimmune haemolytic anaemia associated with mantle cell lymphoma by Eve, Heather E., Rule, Simon A. J.

“…Autoimmune haemolytic anaemia (AIHA) is a well-recognised complication of lymphoproliferative disorders, and has been reported in association with all B and T…”
Get full text

Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia by Danilov, Alexey V, Herbaux, Charles, Walter, Harriet S, Hillmen, Peter, Rule, Simon A, Kio, Ebenezer A, Karlin, Lionel, Dyer, Martin J S, Mitra, Siddhartha S, Yi, Ping Cheng, Humeniuk, Rita, Huang, Xi, Zhou, Ziqian, Bhargava, Pankaj, Jürgensmeier, Juliane M, Fegan, Christopher D

“…Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of…”
Get full text

Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement – a multi‐centre case series from the United Kingdom by Tucker, David L., Naylor, Georgina, Kruger, Anton, Hamilton, Malcolm S., Follows, George, Rule, Simon A.

Get full text

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors by Morschhauser, Franck, Machiels, Jean-Pascal, Salles, Gilles, Rottey, Sylvie, Rule, Simon A J, Cunningham, David, Peyrade, Frederic, Fruchart, Christophe, Arkenau, Hendrik-Tobias, Genvresse, Isabelle, Liu, Li, Köchert, Karl, Shen, Kui, Kneip, Christoph, Peña, Carol E, Grevel, Joachim, Zhang, Jun, Cisternas, Galia, Reschke, Susanne, Granvil, Camille, Awada, Ahmad

“…The PI3K inhibitor copanlisib has efficacy and manageable safety in patients with indolent lymphoma and solid tumors. Pharmacodynamic effects relative to…”
Get full text

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) by Rule, Simon A., Cartron, Guillaume, Fegan, Christopher, Morschhauser, Franck, Han, Lingling, Mitra, Siddhartha, Salles, Gilles, Dyer, Martin J. S.

“…Recent therapeutic advances for mantle cell lymphoma (MCL) include inhibitors of Bruton’s tyrosine kinase (BTK), a critical component in the B-cell receptor…”
Get full text

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059 by Walter, Harriet S., Jayne, Sandrine, Rule, Simon A., Cartron, Guillaume, Morschhauser, Franck, Macip, Salvador, Karlin, Lionel, Jones, Ceri, Herbaux, Charles, Quittet, Philippe, Shah, Nimish, Hutchinson, Claire V., Fegan, Christopher, Yang, Yingsi, Mitra, Siddhartha, Salles, Gilles, Dyer, Martin J.S.

Get full text

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma by Morschhauser, Franck, Dyer, Martin J. S., Walter, Harriet S., Danilov, Alexey V., Ysebaert, Loic, Hodson, Daniel James, Fegan, Christopher, Rule, Simon A., Radford, John, Cartron, Guillaume, Bouabdallah, Krimo, Davies, Andrew John, Spurgeon, Stephen, Rajakumaraswamy, Nishanthan, Li, Biao, Humeniuk, Rita, Huang, Xi, Bhargava, Pankaj, Jürgensmeier, Juliane M., Salles, Gilles

Get full text

Ibrutinib for mantle cell lymphoma by Tucker, David L, Rule, Simon A

“…Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma. Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase…”
Get full text

Does transcutaneous electrical nerve stimulation (TENS) alleviate the pain experienced during bone marrow sampling in addition to standard techniques? A randomised, double-blinded, controlled trial by Tucker, David L, Rockett, Mark, Hasan, Mehedi, Poplar, Sarah, Rule, Simon A

“…Bone marrow aspiration and trephine (BMAT) biopsies remain important tests in haematology. However, the procedures can be moderately to severely painful…”
Get more information

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia by Tucker, David L, Rule, Simon A

“…Although chemo-immunotherapy remains at the forefront of first-line treatment for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), small…”
Get full text

Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma by Eve, Heather E, Furtado, Michelle V, Hamon, Michael D, Rule, Simon A J

Get full text

Position paper on imatinib mesylate in chronic myeloid leukaemia by O'Brien, Stephen G., Rule, Simon A. J.

Get full text

Indolent mantle-cell lymphoma: immunoglobulin variable region heavy chain sequence analysis reveals evidence of disease 10 years prior to symptomatic clinical presentation by Rule, Simon A J, Poplar, Sarah, Evans, Paul A S, O'Connor, Sheila J M, Owen, Roger G

Get full text

Managing cutaneous reactions to imatinib therapy by Rule, Simon A.J., O'Brien, Stephen G., Crossman, Lucy C.

Get full text

Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide±rituximab by Eve, Heather E., Seymour, John F., Rule, Simon A. J.

Get full text

Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study by Eve, Heather E., Linch, David, Qian, Wendi, Ross, Moira, Seymour, John F., Smith, Paul, Stevens, Lindsey, Rule, Simon A. J.

“…The National Cancer Research Network (NCRN) is currently coordinating a Phase III randomised study (LY05) comparing fludarabine and cyclophosphamide (FC) with…”
Get full text

The simplified mantle cell lymphoma international prognostic index predicts overall survival but not progression-free survival in patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide±rituximab: results of a randomized phase II trial by Eve, Heather E., Gambell, Jo, Smith, Paul, Qian, Wendi, Rule, Simon A. J.

Get full text